FDA rejects Delcath’s cancer therapy, asks for more trials

(Reuters) – Delcath Systems Inc said the U.S. Food and Drug Administration rejected its cancer therapy, and asked for more trials, more than four months after a panel of U.S. advisers recommended against its approval. The company also said it fired Chief Executive Eamonn Hobbs on September 10 and appointed two interim co-CEOs. Further studies should show that the treatment is safe and effective based on overall survival, and that benefits outweigh risks, the FDA said. …